These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34301814)

  • 1. Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
    Roulstone V; Mansfield D; Harris RJ; Twigger K; White C; de Bono J; Spicer J; Karagiannis SN; Vile R; Pandha H; Melcher A; Harrington K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
    Berkeley RA; Steele LP; Mulder AA; van den Wollenberg DJM; Kottke TJ; Thompson J; Coffey M; Hoeben RC; Vile RG; Melcher A; Ilett EJ
    Cancer Immunol Res; 2018 Oct; 6(10):1161-1173. PubMed ID: 30209061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
    Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
    Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.
    Peng KW; Myers R; Greenslade A; Mader E; Greiner S; Federspiel MJ; Dispenzieri A; Russell SJ
    Gene Ther; 2013 Mar; 20(3):255-61. PubMed ID: 22476202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.
    Roulstone V; Twigger K; Zaidi S; Pencavel T; Kyula JN; White C; McLaughlin M; Seth R; Karapanagiotou EM; Mansfield D; Coffey M; Nuovo G; Vile RG; Pandha HS; Melcher AA; Harrington KJ
    Gene Ther; 2013 May; 20(5):521-8. PubMed ID: 22895509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
    Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
    Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
    Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
    BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
    Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
    Mohamed A; Smiley JR; Shmulevitz M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
    Ilett E; Kottke T; Donnelly O; Thompson J; Willmon C; Diaz R; Zaidi S; Coffey M; Selby P; Harrington K; Pandha H; Melcher A; Vile R
    Mol Ther; 2014 Oct; 22(10):1851-63. PubMed ID: 24957982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
    Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
    Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
    Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
    Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
    Groeneveldt C; Kinderman P; Griffioen L; Rensing O; Labrie C; van den Wollenberg DJM; Hoeben RC; Coffey M; Loghmani H; Verdegaal EME; Welters MJP; van der Burg SH; van Hall T; van Montfoort N
    Cancer Immunol Res; 2024 Mar; 12(3):334-349. PubMed ID: 38194598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
    Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
    Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
    Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
    Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic viruses for cancer immunotherapy.
    Hemminki O; Dos Santos JM; Hemminki A
    J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
    Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
    Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.